Patients with EMD may be considered for alternative treatments in clinical trials [e.g., cereblon E3 ligase modulators (CELMoDs) (89, 90) or novel combination therapies (91–93)] or tumor debulking [with dexamethasone, cisplatin, doxorubicin, cyclophosphamide and etoposide (DPACE) or a similar regimen (94)] prior to bsAb therapy. Here, CRBN is linked to neoplasm.